Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07268638 · ClinicalTrials.gov registry record · Phase 2
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2 study of Focal Segmental Glomerulosclerosis, sponsored by Akebia Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 8
- Study locations
NCT07268638: Recruiting Phase 2 study of Focal Segmental Glomerulosclerosis, sponsored by Akebia Therapeutics.
NCT07268638 is a Phase 2 study of Focal Segmental Glomerulosclerosis that is actively recruiting participants, run by Akebia Therapeutics. The registered enrollment target is 60 participants, below the 234-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (74% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07268638, a Phase 2 study of Focal Segmental Glomerulosclerosis, is actively recruiting participants, sponsored by Akebia Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Praliciguat
Study Locations (8)
Florida
- Investigator Site #6 - Coral Springs
- Investigator Site #7 - Miami
- Investigator Site #8 - Orlando
California
- Investigator Site #2 - Chula Vista
Georgia
- Investigator Site # 1 - Lawrenceville
Illinois
- Investigator Site #3 - Chicago
Tennessee
- Investigator Site #4 - Chattanooga
Texas
- Investigator Site #5 - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
What NCT07268638 shows while recruiting
NCT07268638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 234-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Focal Segmental Glomerulosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07268638 lists 8 locations in 6 states (Florida, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT07268638 about?
NCT07268638 is a clinical study titled "A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)". This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial ...
What is the current status of trial NCT07268638?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-12-03. Estimated completion is 2028-01.
What conditions does trial NCT07268638 study?
This clinical trial studies the following conditions: Focal Segmental Glomerulosclerosis.
What interventions are being tested in trial NCT07268638?
The interventions under investigation include: Placebo (OTHER), Praliciguat (DRUG).
Who is sponsoring clinical trial NCT07268638?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07268638 being conducted?
This trial has 8 study locations across California, Florida, Georgia, Illinois, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Segmental Glomerulosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07268638's enrollment target sits among peer trials
60 11th of 19 higher than 9 of 19 other Focal Segmental Glomerulosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Focal Segmental Glomerulosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
RECRUITING · Phase 2
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
COMPLETED · Phase 2
-
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI